{"id":"sorafenib-ramp-up-regimen","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hand-foot skin reaction"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"25-35","effect":"Rash"},{"rate":"25-35","effect":"Fatigue"},{"rate":"15-25","effect":"Hypertension"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Anorexia"}]},"_chembl":{"chemblId":"CHEMBL1200485","moleculeType":"Small molecule","molecularWeight":"637.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sorafenib inhibits multiple receptor tyrosine kinases including BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, and c-KIT. By blocking these pathways, it suppresses both tumor cell growth and the formation of new blood vessels that tumors depend on for survival. The ramp-up regimen refers to a dose escalation schedule designed to improve tolerability by gradually increasing from a lower starting dose to the therapeutic dose.","oneSentence":"Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:47.282Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Renal cell carcinoma"},{"name":"Differentiated thyroid cancer"}]},"trialDetails":[{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT01203787","phase":"PHASE4","title":"Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-12","conditions":"Hepatocellular Carcinoma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexavar (Bay43-9006)"],"phase":"marketed","status":"active","brandName":"Sorafenib Ramp-Up Regimen","genericName":"Sorafenib Ramp-Up Regimen","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis. Used for Hepatocellular carcinoma, Renal cell carcinoma, Differentiated thyroid cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}